Novel immunotherapeutics against LGR5 to target multiple cancer types.
Chen HC, Mueller N, Stott K, Kapeni C, Rivers E, Sauer CM, Beke F, Walsh SJ, Ashman N, O'Brien L, Rafati Fard A, Ghodsinia A, Li C, Joud F, Giger O, Zlobec I, Olan I, Aitken SJ, Hoare M, Mair R, Serrao E, Brenton JD, Garcia-Gimenez A, Richardson SE, Huntly B, Spring DR, Skjoedt MO, Skjødt K, de la Roche M, de la Roche M.
Chen HC, et al. Among authors: mair r.
EMBO Mol Med. 2024 Sep;16(9):2233-2261. doi: 10.1038/s44321-024-00121-2. Epub 2024 Aug 21.
EMBO Mol Med. 2024.
PMID: 39169164
Free PMC article.